TRex Bio (NASDAQ:TRXB) Stock Rated “Outperform” in New Coverage at Wedbush

Wedbush assumed coverage on shares of TRex Bio (NASDAQ:TRXB) in a research note released on Monday, Marketbeat Ratings reports. The firm issued an outperform rating and a $30.00 price target on the stock.

TRex Bio Stock Performance

Shares of TRXB opened at $13.55 on Monday. TRex Bio has a fifty-two week low of $12.50 and a fifty-two week high of $16.56.

Insider Buying and Selling

In other TRex Bio news, major shareholder Alexandria Venture Investments acquired 178,571 shares of TRex Bio stock in a transaction that occurred on Tuesday, October 13th. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $2,499,994.00. Following the purchase, the insider owned 1,346,501 shares of the company’s stock, valued at approximately $18,851,014. This represents a 15.29% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

TRex Bio Company Profile

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.